Bristol Myers: acquisition of Mirati Therapeutics finalized
With this transaction, the healthcare group says it is adding the marketed lung cancer drug Krazati (adagrasib) to its oncology portfolio, as well as several other promising clinical assets.
The transaction, announced last October for a total equity value of $4.8 billion, is expected to have a dilutive effect of approximately $0.35 per share on Bristol Myers Squibb's non-GAAP EPS in 2024.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction